<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CRESTOR- rosuvastatin calciumÂ tablet, film coatedÂ </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CRESTOR safely and effectively. See full prescribing information for CRESTOR.<br>CRESTOR (rosuvastatin calcium) tablets<br>Initial U.S. Approval: 2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">CRESTOR is an HMG Coâ€‘A reductase inhibitor indicated for: </p>
<dl>
<dt>â€¢</dt>
<dd>patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> as an adjunct to diet to reduce elevated totalâ€‘C, LDLâ€‘C, ApoB, nonHDLâ€‘C, and TG levels and to increase HDLâ€‘C <a href="#ID_bf46a367-7843-4d8a-8d61-1b04e7706b0f">(1.1)</a>
</dd>
<dt>â€¢</dt>
<dd>patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> as an adjunct to diet <a href="#ID_f3f4a9ae-1fd2-41e0-b7e5-af480f30e76a">(1.2)</a>
</dd>
<dt>â€¢</dt>
<dd>patients with primary dysbetalipoproteinemia (TypeÂ III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipoproteinemia</span>) as an adjunct to diet <a href="#ID_6e551ef3-2236-4801-8d13-6371376aa10f">(1.3)</a>
</dd>
<dt>â€¢</dt>
<dd>patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> (HoFH) to reduce LDLâ€‘C, total-C, and ApoB  <a href="#ID_bfb48c7e-565e-46e2-afa4-51ead454eeb4">(1.4)</a>
</dd>
<dt>â€¢</dt>
<dd>slowing the progression of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> as part of a treatment strategy to lower totalâ€‘C and LDLâ€‘C as an adjunct to diet <a href="#ID_fcf92dba-58e4-46ef-b8e2-ba2c7b69ec27">(1.5)</a>
</dd>
<dt>â€¢</dt>
<dd>pediatric patients 10Â toÂ 17Â years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH) to reduce elevated totalâ€‘C, LDLâ€‘C and ApoB after failing an adequate trial of diet therapy <a href="#ID_bf46a367-7843-4d8a-8d61-1b04e7706b0f">(1.1)</a>
</dd>
<dt>â€¢</dt>
<dd>risk reduction of MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors <a href="#ID_59306fb2-c2b0-4bb7-9a69-0269ffd1010e">(1.6)</a>
</dd>
</dl>
<p class="Highlighta">Limitations of use <a href="#ID_384b38a8-5c92-47cb-a821-73adc6c18854">(1.7)</a>: </p>
<dl>
<dt>â€¢</dt>
<dd>CRESTOR has not been studied in Fredrickson Type I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>CRESTOR can be taken with or without food, at any time of day. <a href="#ID_fbfff8d7-258e-4dfb-9f8e-738004da3197">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Dose range: 5â€‘40 mg once daily. Use 40Â mg dose only for patients not reaching LDLâ€‘C goal with 20Â mg. <a href="#ID_fbfff8d7-258e-4dfb-9f8e-738004da3197">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">HoFH:</span> Starting dose 20Â mg. <a href="#ID_a794f27c-3b53-4d7c-bfd0-b43094614e2a">(2.3)</a>
</dd>
<dt>â€¢</dt>
<dd>In pediatric patients 10Â toÂ 17 years of age with HeFH, the usual dose range is 5â€‘20Â mg/day; doses greater than 20Â mg have not been studied in this patient population. <a href="#ID_9611d352-8b97-40f0-8459-ab4d3f047f38">(2.2)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 5Â mg, 10Â mg, 20Â mg, and 40Â mg (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to product components <a href="#tylerr1186685883109">(4)</a>
</dd>
<dt>â€¢</dt>
<dd>Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels <a href="#tylerr1186685883109">(4)</a>
</dd>
<dt>â€¢</dt>
<dd>Women who are pregnant or may become pregnant (<a href="#tylerr1186685883109">4</a>, <a href="#williamsonbk1194552840517">8.1</a>)</dd>
<dt>â€¢</dt>
<dd>Nursing mothers (<a href="#tylerr1186685883109">4</a>, <a href="#williamsonbk1194552865892">8.3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>):</span> Risks increase with use of 40Â mg dose, advanced age (â‰¥65), <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and combination use with cyclosporine, atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir. Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported.  Advise patients to promptly report to their physician unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and discontinue CRESTOR if signs or symptoms appear. (<a href="#tylerr1187016417948">5.1</a>, <a href="#williamsonbk1194552963313">7.5</a>, <a href="#williamsonbk1195052282556">7.6</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Liver enzyme abnormalities:</span> Persistent elevations in hepatic transaminases can occur. Perform liver enzyme tests before initiating therapy and as clinically indicated thereafter. <a href="#williamsonbk1194552824314">(5.2)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most frequent adverse reactions (rateÂ <span class="Underline">&gt;</span>Â 2%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <a href="#williamsonbk1194552813204">(6.1)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Cyclosporine: </span> Combination increases rosuvastatin exposure. Limit CRESTOR dose to 5Â mg once daily. (<a href="#williamsonbk1194553149468">2.5</a>, <a href="#tylerr1187016417948">5.1</a>,<a href="#ID_429c1942-85b8-410f-911d-c7082b0cba0b">7.1</a>, <a href="#williamsonbk1194552696814">12.3</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Gemfibrozil:</span> Combination should be avoided. If used together, limit CRESTOR dose to 10Â mg once daily. (<a href="#tylerr1187016417948">5.1</a>, <a href="#williamsonbk1195052126465">7.2</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: </span> Combination increases rosuvastatin exposure. Limit CRESTOR dose to 10Â mg once daily. (<a href="#williamsonbk1194553149468">2.5</a>, <a href="#tylerr1187016417948">5.1</a>, <a href="#williamsonbk1194552763345">7.3</a>, <a href="#williamsonbk1194552696814">12.3</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Coumarin anticoagulants:</span> Combination prolongs INR. Achieve stable INR prior to starting CRESTOR. Monitor INR frequently until stable upon initiation or alteration of CRESTOR therapy. (<a href="#williamsonbk1194553111202">5.3</a>, <a href="#williamsonbk1194552734783">7.4</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Concomitant lipid-lowering therapies: </span> Use with fibrates or lipid-modifying doses (â‰¥1Â g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with CRESTOR. (<a href="#tylerr1187016417948">5.1</a>, <a href="#williamsonbk1194552963313">7.5</a>, <a href="#williamsonbk1195052282556">7.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (not on hemodialysis):</span>  Starting dose is 5Â mg, not to exceed 10Â mg. (<a href="#williamsonbk1194553382591">2.6</a>, <a href="#tylerr1187016417948">5.1</a>, <a href="#williamsonbk1194552782845">8.6</a>)</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Asian population: </span> Consider 5Â mg starting dose. (<a href="#williamsonbk1194553455607">2.4</a>, <a href="#williamsonbk1194552682158">8.8</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Primary Dysbetalipoproteinemia (Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipoproteinemia</span>)</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5 Slowing of the Progression of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span></a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Primary Prevention of Cardiovascular Disease</a></h2>
<h2><a href="#section-1.7" class="toc">1.7 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10Â toÂ 17 years of age)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosing in Asian Patients</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Use with Concomitant Therapy</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Dosing in Patients with Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Skeletal Muscle Effects</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Enzyme Abnormalities</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Concomitant Coumarin Anticoagulants</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Endocrine Effects</a></h2>
<h1><a href="#section-6" class="toc">6ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Pediatric patients 10Â toÂ 17 years of age</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cyclosporine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Gemfibrozil</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Protease Inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Coumarin Anticoagulants</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Niacin</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Fenofibrate</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Colchicine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Asian Patients</a></h2>
<h1><a href="#section-9" class="toc">10OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology  and/or Pharmacology </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Primary Dysbetalipoproteinemia (Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipoproteinemia</span>)</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Pediatric Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></a></h2>
<h2><a href="#section-13.7" class="toc">14.7 Slowing of the Progression of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span></a></h2>
<h2><a href="#section-13.8" class="toc">14.8 Primary Prevention of Cardiovascular Disease</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Skeletal Muscle Effects</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Concomitant Use of Antacids</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Pregnancy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="tylerr1190051416908"></a><a name="section-1"></a><p></p>
<h1>1INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf46a367-7843-4d8a-8d61-1b04e7706b0f"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></h2>
<p class="First">CRESTOR is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDLâ€‘C, and triglycerides and to increase HDLâ€‘C in adult patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> when response to diet and nonpharmacological interventions alone has been inadequate. </p>
<p><span class="Bold">Pediatric Patients 10Â toÂ 17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> (HeFH) </span></p>
<p>Adjunct to diet to reduce Totalâ€‘C, LDLâ€‘C and ApoB levels in adolescent boys and girls, who are at least one year post-<span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>, 10â€‘17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> if after an adequate trial of diet therapy the following findings are present: LDLâ€‘CÂ &gt; 190 mg/dL or &gt;Â 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f3f4a9ae-1fd2-41e0-b7e5-af480f30e76a"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e551ef3-2236-4801-8d13-6371376aa10f"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Primary Dysbetalipoproteinemia (Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipoproteinemia</span>)</h2>
<p class="First">CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (TypeÂ IIIÂ <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipoproteinemia</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bfb48c7e-565e-46e2-afa4-51ead454eeb4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDLâ€‘C, Totalâ€‘C, and ApoB in adult patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fcf92dba-58e4-46ef-b8e2-ba2c7b69ec27"></a><a name="section-1.5"></a><p></p>
<h2>1.5 Slowing of the Progression of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span></h2>
<p class="First">CRESTOR is indicated as adjunctive therapy to diet to slow the progression of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> in adult patients as part of a treatment strategy to lower Totalâ€‘C and LDLâ€‘C to target levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_59306fb2-c2b0-4bb7-9a69-0269ffd1010e"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Primary Prevention of Cardiovascular Disease</h2>
<p class="First">In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age â‰¥Â 50 years old in men and â‰¥Â 60 years old in women, hsCRPÂ â‰¥Â 2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, low HDLâ€‘C, smoking, or a family history of premature coronary heart disease, CRESTOR is indicated to:</p>
<dl>
<dt>â€¢</dt>
<dd>reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
<dt>â€¢</dt>
<dd>reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></dd>
<dt>â€¢</dt>
<dd>reduce the risk of arterial revascularization procedures</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_384b38a8-5c92-47cb-a821-73adc6c18854"></a><a name="section-1.7"></a><p></p>
<h2>1.7 Limitations of Use</h2>
<p class="First">CRESTOR has not been studied in Fredrickson TypeÂ I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="tylerr1187016457870"></a><a name="section-2"></a><p></p>
<h1>2DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fbfff8d7-258e-4dfb-9f8e-738004da3197"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First">The dose range for CRESTOR is 5Â toÂ 40Â mg orally once daily. The usual starting dose is 10â€‘20Â mg.</p>
<p>CRESTOR can be administered as a single dose at any time of day, with or without food. The tablet should be swallowed whole.</p>
<p>When initiating CRESTOR therapy or switching from another HMGâ€‘CoA reductase inhibitor therapy, the appropriate CRESTOR starting dose should first be utilized, and only then titrated according to the patientâ€™s response and individualized goal of therapy. </p>
<p>After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2Â toÂ 4Â weeks and the dosage adjusted accordingly.</p>
<p>The 40Â mg dose of CRESTOR should be used only for those patients who have not achieved their LDLâ€‘C goal utilizing the 20Â mg dose [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9611d352-8b97-40f0-8459-ab4d3f047f38"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10Â toÂ 17 years of age)</h2>
<p class="First">The usual dose range of CRESTOR is 5â€‘20 mg/day; the maximum recommended dose is 20Â mg/day (doses greater than 20Â mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see<span class="Italics"><a href="#tylerr1190121854750">Clinical Pharmacology (12)</a></span> and <span class="Italics"><a href="#ID_f3f4a9ae-1fd2-41e0-b7e5-af480f30e76a">Indications and Usage (1.2)</a></span>]. Adjustments should be made at intervals of 4Â weeks or more.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a794f27c-3b53-4d7c-bfd0-b43094614e2a"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">The recommended starting dose of CRESTOR is 20Â mg once daily. Response to therapy should be estimated from preapheresis LDLâ€‘C levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194553455607"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosing in Asian Patients</h2>
<p class="First">In Asian patients, consider initiation of CRESTOR therapy with 5Â mg once daily due to increased rosuvastatin plasma concentrations.  The increased systemic exposure should be taken into consideration when treating Asian patients not adequately controlled at doses up to 20Â mg/day. [see<span class="Italics"><a href="#williamsonbk1194552682158">Use in Specific Populations (8.8)</a></span> and<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194553149468"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Use with Concomitant Therapy</h2>
<p class="First"><span class="Italics">Patients taking cyclosporine</span></p>
<p>The dose of CRESTOR should not exceed 5Â mg once daily [see <span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>,  <span class="Italics"><a href="#ID_429c1942-85b8-410f-911d-c7082b0cba0b">Drug Interactions (7.1)</a></span>, and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
<p><span class="Italics">Patients taking gemfibrozil</span></p>
<p>Initiate CRESTOR therapy with 5Â mg once daily.  The dose of CRESTOR should not exceed 10Â mg once daily [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#williamsonbk1195052126465">Drug Interactions (7.2)</a></span>, and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
<p><span class="Italics">Patients taking atazanavir and ritonavir, lopinavir and ritonavir, or simeprevir</span></p>
<p>Initiate CRESTOR therapy with 5Â mg once daily.  The dose of CRESTOR should not exceed 10Â mg once daily [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>,  <span class="Italics"><a href="#williamsonbk1194552763345">Drug Interactions (7.3),</a></span> and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194553382591"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Dosing in Patients with Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span>Â &lt;30Â mL/min/1.73Â m<span class="Sup">2</span>) not on hemodialysis, dosing of CRESTOR should be started at 5Â mg once daily and not exceed 10Â mg once daily [see<span class="Italics"><a href="#williamsonbk1194552782845">Use in Specific Populations (8.6)</a></span> and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_24675f17-bf90-4b12-a3c5-3151feeaff87"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">5Â mg: Yellow, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ5â€? on one side of the tablet.</p>
<p>10Â mg: Pink, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ10â€? on one side of the tablet.</p>
<p>20Â mg: Pink, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ20â€? on one side of the tablet.</p>
<p>40Â mg: Pink, oval, biconvex, coated tablets. Debossed â€œCRESTORâ€? on one side and â€œ40â€? on the other side of the tablet.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="tylerr1186685883109"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">CRESTOR is contraindicated in the following conditions:</p>
<dl>
<dt>â€¢</dt>
<dd>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been reported with CRESTOR [see<span class="Italics"><a href="#williamsonbk1194552813204">Adverse Reactions (6.1)</a></span>].</dd>
<dt>â€¢</dt>
<dd>Patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels [see<span class="Italics"><a href="#williamsonbk1194552824314">Warnings and Precautions (5.2)</a></span>].</dd>
<dt>â€¢</dt>
<dd>Women who are pregnant or may become pregnant.  Because HMGâ€‘CoA reductase inhibitors decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, CRESTOR may cause fetal harm when administered to pregnant women.  Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established.  If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy [see<span class="Italics"><a href="#williamsonbk1194552840517">Use in Specific Populations (8.1)</a></span> and <span class="Italics"><a href="#williamsonbk1194552853517">Nonclinical Toxicology (13.2)</a></span>].</dd>
<dt>â€¢</dt>
<dd>Nursing mothers. Because another drug in this class passes into breast milk, and because HMGâ€‘CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require CRESTOR treatment should be advised not to nurse their infants [see<span class="Italics"><a href="#williamsonbk1194552865892">Use in Specific Populations (8.3)</a></span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="tylerr1187016578885"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="tylerr1187016417948"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Skeletal Muscle Effects</h2>
<p class="First"><span class="Bold">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40Â mg). </span></p>
<p>CRESTOR should be prescribed with caution in patients with predisposing factors for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (e.g., ageÂ â‰¥Â 65 years, inadequately treated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>). </p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir [see<span class="Italics"><a href="#tylerr1187016457870">Dosage and Administration (2)</a></span> and <span class="Italics"><a href="#tylerr1190121738234">Drug Interactions  (7</a></span>)].  Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with HMG-CoA reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be exercised when prescribing CRESTOR with colchicine [see <span class="Italics"><a href="#ID_0446dc56-2670-41e9-a4c2-ff97b622a920">Drug Interactions (7.7)</a></span>].</p>
<p>CRESTOR therapy should be discontinued if markedly elevated creatine kinase levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. CRESTOR therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, major surgery, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>).</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use. IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; improvement with immunosuppressive agents. </p>
<p>All patients should be advised to promptly report to their physician unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing CRESTOR. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552824314"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Enzyme Abnormalities</h2>
<p class="First">It is recommended that liver enzyme tests be performed before the initiation of CRESTOR, and if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur.</p>
<p>Increases in serum transaminases [AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) or ALT (SGPT)] have been reported with HMGâ€‘CoA reductase inhibitors, including CRESTOR. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. There were two cases of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, for which a relationship to CRESTOR therapy could not be determined, which resolved after discontinuation of therapy. There were no cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> or irreversible liver disease in these trials. </p>
<p>In a pooled analysis of placebo-controlled trials, increases in serum transaminases to &gt;3 times the upper limit of normal occurred in 1.1% of patients taking CRESTOR versus 0.5% of patients treated with placebo. </p>
<p>There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including rosuvastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with CRESTOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart CRESTOR. </p>
<p>CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> [see<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)].</a></span> Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of CRESTOR [see <span class="Italics"><a href="#tylerr1186685883109">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194553111202"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Concomitant Coumarin Anticoagulants</h2>
<p class="First">Caution should be exercised when anticoagulants are given in conjunction with CRESTOR because of its potentiation of the effect of coumarin-type anticoagulants in prolonging the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR.  In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs [see<span class="Italics"><a href="#williamsonbk1194552734783">Drug Interactions (7.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194553243733"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></h2>
<p class="First">In the CRESTOR clinical trial program, dipstick-positive <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">microscopic hematuria</span> were observed among CRESTOR treated patients. These findings were more frequent in patients taking CRESTOR 40Â mg, when compared to lower doses of CRESTOR or comparator HMGâ€‘CoA reductase inhibitors, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, a dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and/or <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> during routine urinalysis testing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_44a9d1f9-6b10-4ce3-bd1c-e25f0597c23e"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Endocrine Effects</h2>
<p class="First">Increases in HbA1c and fasting serum glucose levels have been reported with HMGâ€‘CoA reductase inhibitors, including CRESTOR. Based on clinical trial data with CRESTOR, in some instances these increases may exceed the threshold for the diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus [see<span class="Italics"><a href="#williamsonbk1194552813204">Adverse Reactions (6.1)</a></span>].</p>
<p>Although clinical studies have shown that CRESTOR alone does not reduce basal plasma cortisol concentration or impair adrenal reserve, caution should be exercised if CRESTOR is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="tylerr1190122686140"></a><a name="section-6"></a><p></p>
<h1>6ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label: </p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (including <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>) [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Liver enzyme abnormalities [see<span class="Italics"><a href="#williamsonbk1194552824314">Warnings and Precautions (5.2)</a></span>]</dd>
</dl>
<p>In the CRESTOR controlled clinical trials database (placebo or active-controlled) of 5394Â patients with a mean treatment duration of 15Â weeks, 1.4% of patients discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
</dl>
<p>The most commonly reported adverse reactions (incidence â‰¥Â 2%) in the CRESTOR controlled clinical trial database of 5394Â patients were: </p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552813204"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. </p>
<p>Adverse reactions reported in â‰¥Â 2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 1.  These studies had a treatment duration of up to 12Â weeks. </p>
<dl>
<dt>Â </dt>
<dd>Table . Adverse Reactions<span class="Italics"><span class="Sup">1</span></span> Reported in â‰¥Â 2% of Patients Treated with CRESTOR and &gt;Â Placebo in Placeboâ€‘Controlled Trials (%Â of Patients)</dd>
</dl>
<table width="100%">
<col width="20%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="19%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Adverse Reactions</span></p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">CRESTOR</span></p>
<p><span class="Bold">5Â mg</span></p>
<p><span class="Bold">N=291</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">CRESTOR</span></p>
<p><span class="Bold">10Â mg</span></p>
<p><span class="Bold">N=283</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">CRESTOR</span></p>
<p><span class="Bold">20Â mg</span></p>
<p><span class="Bold">N=64</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">CRESTOR</span></p>
<p><span class="Bold">40Â mg</span></p>
<p><span class="Bold">N=106</span></p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Total CRESTOR</span></p>
<p><span class="Bold">5Â mg</span>â€‘<span class="Bold">40Â mg</span></p>
<p><span class="Bold">N=744</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N=382</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.9</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.4</p></td>
</tr>
</tbody>
</table>
<p>Other adverse reactions reported in clinical studies were <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.  The following laboratory abnormalities have also been reported: dipstick-positive <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">microscopic hematuria</span> [see<span class="Italics"><a href="#williamsonbk1194553243733">Warnings and Precautions (5.4)</a></span>]; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.  </p>
<p>In the METEOR study, involving 981 participants treated with rosuvastatin 40Â mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years, 5.6% of subjects treated with CRESTOR versus 2.8% of placebo-treated subjects discontinued due to adverse reactions.  The most common adverse reactions that led to treatment discontinuation were: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, hepatic enzyme increased, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> [see<span class="Italics"><a href="#williamsonbk1194897890156">Clinical Studies (14.7)</a></span>].</p>
<p>Adverse reactions reported in â‰¥Â 2% of patients and at a rate greater than placebo are shown in TableÂ 2.</p>
<dl>
<dt>Â </dt>
<dd>Table . Adverse Reactions<span class="Italics"><span class="Sup">1</span></span> Reported in â‰¥2% of Patients Treated with CRESTOR and &gt;Â Placebo in the METEOR Trial (% of Patients)</dd>
</dl>
<table width="100%">
<col width="41%">
<col width="39%">
<col width="20%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reactions</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">CRESTOR 40Â mg </span><br><span class="Bold">N=700</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">N=281</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Frequency recorded as abnormal laboratory value.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">12.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">10.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Increased CPK</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">ALT &gt;3x ULN<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.7</p></td>
</tr>
</tbody>
</table>
<p>In the JUPITER study, 17,802 participants were treated with rosuvastatin 20Â mg (n=8901) or placebo (n=8901) for a mean duration of 2 years. A higher percentage of rosuvastatin-treated patients versus placebo-treated patients, 6.6% and 6.2%, respectively, discontinued study medication due to an adverse event, irrespective of treatment causality. <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> was the most common adverse reaction that led to treatment discontinuation. </p>
<p>In JUPITER, there was a significantly higher frequency of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus reported in patients taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1cÂ &gt; 6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated patients [see<span class="Italics"><a href="#ID_44a9d1f9-6b10-4ce3-bd1c-e25f0597c23e">Warnings and Precautions (5.5)</a></span> and <span class="Italics"><a href="#ID_f858b2a7-3707-40d9-9002-bf31f98aaf0c">Clinical Studies (14.8)</a></span>]. </p>
<p>Adverse reactions reported in â‰¥Â 2% of patients and at a rate greater than placebo are shown in TableÂ 3.</p>
<dl>
<dt>Â </dt>
<dd>Table . Adverse Reactions<span class="Italics"><span class="Sup">1</span></span> Reported in â‰¥Â 2% of Patients Treated with CRESTOR and &gt;Â Placebo in the JUPITER Trial (%Â of Patients)</dd>
</dl>
<table width="100%">
<col width="41%">
<col width="39%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Adverse Reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">CRESTOR 20Â mg</span></p>
<p><span class="Bold">N=8901</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N=8901</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.3</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_214986be-5597-4674-b35b-d5bd70cbf136"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Pediatric patients 10Â toÂ 17 years of age</h2>
<p class="First">In a 12-week controlled study in boys and postmenarchal girls, the safety and tolerability profile of CRESTOR 5Â toÂ 20Â mg daily was generally similar to that of placebo [see<span class="Italics"><a href="#_Ref">Clinical Studies (14.6)</a></span> and <span class="Italics"><a href="#ID_c4d5e84a-309e-4463-8f7c-3371a1cd7f9f">Use in Specific Populations, Pediatric Use (8.4)</a></span>].  </p>
<p>However, elevations in serum creatine phosphokinase (CK)Â &gt; 10Â xÂ ULN were observed more frequently in rosuvastatin compared with placebo-treated children. FourÂ ofÂ 130Â (3%) children treated with rosuvastatin (2Â treated with 10Â mg and 2Â treated with 20Â mg) had increased CKÂ &gt;10Â xÂ ULN, compared to 0Â ofÂ 46 children on placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6c2bcf62-93f6-4559-af83-8a7ca548ad82"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of CRESTOR: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span> (including <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>), <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [see <span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>].</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1Â dayÂ toÂ years) and symptom resolution (median of 3Â weeks).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="tylerr1190121738234"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_429c1942-85b8-410f-911d-c7082b0cba0b"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cyclosporine</h2>
<p class="First">Cyclosporine increased rosuvastatin exposure (AUC) 7â€‘fold.  Therefore, in patients taking cyclosporine, the dose of CRESTOR should not exceed 5Â mg once daily [see<span class="Italics"><a href="#williamsonbk1194553149468">Dosage and Administration (2.5)</a></span>, <span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>, and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1195052126465"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Gemfibrozil</h2>
<p class="First">Gemfibrozil significantly increased rosuvastatin exposure. Due to an observed increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, combination therapy with CRESTOR and gemfibrozil should be avoided. If used together, the dose of CRESTOR should not exceed 10Â mg once daily  [see<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552763345"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Protease Inhibitors</h2>
<p class="First">Coadministration of rosuvastatin with certain protease inhibitors has differing effects on rosuvastatin exposure. Simeprevir, which is a <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV) protease inhibitor, or combinations of atazanavir/ritonavir or lopinavir/ritonavir, which are HIV-1 protease inhibitors,  increase rosuvastatin exposure (AUC) up to threefold [see Table 4 â€“<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology  (12.3)</a></span>]. For these protease inhibitors, the dose of CRESTOR should not exceed 10Â mg once daily. The combinations of fosamprenavir/ritonavir or tipranavir/ritonavir, which are HIV-1 protease inhibitors, produce little or no change in rosuvastatin exposure. Caution should be exercised when rosuvastatin is coadministered with protease inhibitors [see<span class="Italics"><a href="#williamsonbk1194553149468">Dosage and Administration (2.5),</a><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span> and<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology  (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552734783"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Coumarin Anticoagulants</h2>
<p class="First">CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. Therefore, caution should be exercised when coumarin anticoagulants are given in conjunction with CRESTOR.  In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs [see<span class="Italics"><a href="#williamsonbk1194553111202">Warnings and Precautions (5.3)</a></span> and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552963313"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Niacin</h2>
<p class="First">The risk of skeletal muscle effects may be enhanced when CRESTOR is used in combination with lipid-modifying doses (â‰¥1Â g/day) of niacin; caution should be used when prescribing with CRESTOR [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1195052282556"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Fenofibrate</h2>
<p class="First">When CRESTOR was coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed. Because it is known that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should be used when prescribing fenofibrates with CRESTOR [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span> and<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0446dc56-2670-41e9-a4c2-ff97b622a920"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Colchicine</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with HMGâ€‘CoA reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be exercised when prescribing CRESTOR with colchicine [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_36b54ec3-8dab-4828-91f2-9281b7609804"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="williamsonbk1194552840517"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_88e4290d-5904-4856-b468-c2f845cb046d"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Teratogenic effects: Pregnancy Category X.</span></h3>
<p class="First">CRESTOR is contraindicated in women who are or may become pregnant. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> products are essential for fetal development.  <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> therapy [see<span class="Italics"><a href="#tylerr1186685883109">Contraindications (4)</a></span>]. </p>
<p>There are no adequate and well-controlled studies of CRESTOR in pregnant women. There have been rare reports of congenital anomalies following intrauterine exposure to HMGâ€‘CoA reductase inhibitors. In a review of about 100 prospectively followed pregnancies in women exposed to other HMGâ€‘CoA reductase inhibitors, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-fourfold increased risk of congenital anomalies over background incidence.  In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified. </p>
<p>Rosuvastatin crosses the placenta in rats and rabbits.  In rats, CRESTOR was not teratogenic at systemic exposures equivalent to a human therapeutic dose of 40Â mg/day.  At 10â€‘12 times the human dose of 40Â mg/day, there was decreased pup survival, decreased fetal body weight among female pups, and delayed ossification.  In rabbits, pup viability decreased and maternal mortality increased at doses equivalent to the human dose of 40Â mg/day [see<span class="Italics"><a href="#williamsonbk1194552853517">Nonclinical Toxicology (13.2)</a></span>].</p>
<p>CRESTOR may cause fetal harm when administered to a pregnant woman. If the patient becomes pregnant while taking CRESTOR, the patient should be apprised of the potential risks to the fetus and the lack of known clinical benefit with continued use during pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="williamsonbk1194552865892"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether rosuvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk.  In rats, breast milk concentrations of rosuvastatin are three times higher than plasma levels; however, animal breast milk drug levels may not accurately reflect human breast milk levels.  Because another drug in this class passes into human milk and because HMGâ€‘CoA reductase inhibitors have a potential to cause serious adverse reactions in nursing infants, women who require CRESTOR treatment should be advised not to nurse their infants [see<span class="Italics"><a href="#tylerr1186685883109">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_c4d5e84a-309e-4463-8f7c-3371a1cd7f9f"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of CRESTOR in patients 10Â toÂ 17Â years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> were evaluated in a controlled clinical trial of 12Â weeks duration followed by 40Â weeks of open-label exposure. Patients treated with 5Â mg, 10Â mg, and 20Â mg daily CRESTOR had an adverse experience profile generally similar to that of patients treated with placebo [see<span class="Italics"><a href="#ID_214986be-5597-4674-b35b-d5bd70cbf136">Adverse Reactions (6.2)</a></span>]. Although not all adverse reactions identified in the adult population have been observed in clinical trials of children and adolescent patients, the same warnings and precautions for adults should be considered for children and adolescents. There was no detectable effect of CRESTOR on growth, weight, BMI (body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index), or sexual maturation [see<span class="Italics"><a href="#ID_baea7090-0850-4553-b00f-b8d122f72e37">Clinical Studies (14.5)</a></span>] in pediatric patients (10Â toÂ 17Â years of age). Adolescent females should be counseled on appropriate contraceptive methods while on CRESTOR therapy [see<span class="Italics"><a href="#williamsonbk1194552840517">Use in Specific Populations (8.1)</a></span>]. CRESTOR has not been studied in controlled clinical trials involving prepubertal patients or patients younger than 10Â years of age. Doses of CRESTOR greater than 20 Â mg have not been studied in the pediatric population. </p>
<p>In children and adolescents with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span> experience is limited to eight patients (aged 8Â years and above).  </p>
<p>In a pharmacokinetic study, 18Â patients (9 boys and 9 girls) 10Â toÂ 17Â years of age with heterozygous FH received single and multiple oral doses of CRESTOR. Both C<span class="Sub">max</span> and AUC of rosuvastatin were similar to values observed in adult subjects administered the same doses.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_d981ae09-cd45-4c6b-9ade-6a5793a41030"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 10,275 patients in clinical studies with CRESTOR, 3159 (31%) were 65 years and older, and 698 (6.8%) were 75Â years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.  </p>
<p>Elderly patients are at higher risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and CRESTOR should be prescribed with caution in the elderly [see<span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552782845"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Rosuvastatin exposure is not influenced by mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span>Â â‰¥ 30Â mL/min/1.73 m<span class="Sup">2</span>); however, exposure to rosuvastatin is increased to a clinically significant extent in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who are not receiving hemodialysis. CRESTOR dosing should be adjusted in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span>Â &lt; 30Â mL/min/1.73Â m<span class="Sup">2</span>) not requiring hemodialysis [see<span class="Italics"><a href="#williamsonbk1194553382591">Dosage and Administration (2.6)</a></span>, <span class="Italics"><a href="#tylerr1187016417948">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology  (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0c3f3988-4d40-4d53-9c7f-a9670849ac8e"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">CRESTOR is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels. Chronic alcohol liver disease is known to increase rosuvastatin exposure; CRESTOR should be used with caution in these patients [see<span class="Italics"><a href="#tylerr1186685883109">Contraindications (4)</a></span>, <span class="Italics"><a href="#williamsonbk1194552824314">Warning and Precautions  (5.2)</a></span>, and<span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194552682158"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Asian Patients</h2>
<p class="First">Pharmacokinetic studies have demonstrated an approximate 2â€‘fold increase in median exposure to rosuvastatin in Asian subjects when compared with Caucasian controls. CRESTOR dosage should be adjusted in Asian patients [see<span class="Italics"><a href="#williamsonbk1194553455607">Dosage and Administration (2.4)</a></span> and <span class="Italics"><a href="#williamsonbk1194552696814">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_c7f996ca-0736-4603-8c86-f8325b9885a7"></a><a name="section-9"></a><p></p>
<h1>10OVERDOSAGE</h1>
<p class="First">There is no specific treatment in the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis does not significantly enhance clearance of rosuvastatin.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_b0f3f326-826c-4849-af5e-ccca95cd5f18"></a><a name="section-10"></a><p></p>
<h1>11DESCRIPTION</h1>
<p class="First">CRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration. </p>
<p>The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:</p>
<div class="Figure">
<a name="id1436"></a><img alt="strucural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2c1a3c18-fa77-401b-8784-8e18b0d862f1&amp;name=3a498c46-5ad2-416a-875e-18e48b586954-01.jpg">
</div>
<p>The empirical formula for rosuvastatin calcium is (C<span class="Sub">22</span>H<span class="Sub">27</span>FN<span class="Sub">3</span>O<span class="Sub">6</span>S)<span class="Sub">2</span>Ca and the molecular weight isÂ 1001.14. Rosuvastatin calcium is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of Â 0.13 at pH ofÂ 7.0. </p>
<p>CRESTOR Tablets for oral administration contain 5, 10, 20, or 40Â mg of rosuvastatin and the following inactive ingredients: Each tablet contains: microcrystalline cellulose NF, lactose monohydrate NF, tribasic calcium phosphate NF, crospovidone NF, magnesium stearate NF, hypromellose NF, triacetin NF, titanium dioxide USP, yellow ferric oxide, and red ferric oxide NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="tylerr1190121854750"></a><a name="section-11"></a><p></p>
<h1>12CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_8223a94a-d24a-46e9-a1df-e125de0de4a6"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">CRESTOR is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3â€‘hydroxyâ€‘3â€‘methylglutaryl coenzyme A to mevalonate, a precursor of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.  <span class="Italics">In vivo</span> studies in animals, and <span class="Italics">in vitro</span> studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering.  In <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span> studies, rosuvastatin produces its lipid-modifying effects in two ways.  First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL.  Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="williamsonbk1194552696814"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Absorption:</span></span> In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5Â hours following oral dosing. Both C<span class="Sub">max </span> and AUC increased in approximate proportion to CRESTOR dose. The absolute bioavailability of rosuvastatin is approximately 20%. </dd>
<dt>Â </dt>
<dd>Administration of CRESTOR with food did not affect the AUC of rosuvastatin.   </dd>
<dt>Â </dt>
<dd>The AUC of rosuvastatin does not differ following evening or morning drug administration.</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Distribution:</span></span> Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Metabolism:</span></span> Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \Â 2C9, and <span class="Italics">in vitro</span> studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMGâ€‘CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMGâ€‘CoA reductase inhibitory activity is accounted for by the parent compound.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Excretion:</span></span> Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). The elimination half-life (t<span class="Sub">1/2</span>) of rosuvastatin is approximately 19 hours. </dd>
<dt>Â </dt>
<dd>After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Race:</span></span> A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2â€‘fold elevation in median exposure (AUC and C<span class="Sub">max</span>) in Asian subjects when compared with a Caucasian control group.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Gender:</span></span> There were no differences in plasma concentrations of rosuvastatin between men and women.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Geriatric:</span></span> There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age â‰¥65Â years).</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span></span> Mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span>Â â‰¥Â 30Â mL/min/1.73 m<span class="Sup">2</span>) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3â€‘fold) in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span>Â &lt;Â 30 mL/min/1.73 m<span class="Sup">2</span>) not receiving hemodialysis compared with healthy subjects (CL<span class="Sub">cr</span>Â &gt; 80Â mL/min/1.73Â m<span class="Sup">2</span>).</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics">Hemodialysis:</span></span> Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span></span> In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.</dd>
<dt>Â </dt>
<dd>In patients with Childâ€‘Pugh A disease, C<span class="Sub">max</span> and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Childâ€‘Pugh B disease, C<span class="Sub">max</span> and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.</dd>
</dl>
<p class="First"><span class="Bold"><span class="Italics">Drug-Drug Interactions: </span></span></p>
<p>Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.</p>
<p>Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein  (BCRP).  Concomitant administration of CRESTOR with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma concentrations and an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> [see <span class="Italics"><a href="#williamsonbk1194553149468">Dosage and Administration (2.5)</a></span>]. It is recommended that prescribers consult the relevant product information when considering administration of such products together with CRESTOR.</p>
<a name="_RefID0EDWBG"></a><table width="100%">
<caption><span>Table 4. Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure</span></caption>
<col width="46%">
<col width="21%">
<col width="17%">
<col width="16%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Single dose unless otherwise noted.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Coadministered drug and dosing regimen</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Rosuvastatin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Mean Ratio (ratio with/without coadministered drug) No Effect = 1.0</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Dose (mg)</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Change in AUC</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Cyclosporine â€“ stable dose required (75Â mg â€“ 200Â mgÂ BID)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10Â mg QD for 10Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.1</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>11</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Atazanavir/ritonavir combination 300Â mg/100Â mgÂ QD for 8Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3.1</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>7</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Simeprevir 150 mg QD, 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg, single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.8<br>(2.3-3.4)</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>3.2</dd>
<dt>Â </dt>
<dd>(2.6-3.9)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Lopinavir/ritonavir combination 400Â mg/100Â mgÂ BID for 17Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">20Â mgÂ QD for 7Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">2.1</p>
<p>(1.7-2.6)</p>
</td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>5</dd>
<dt>Â </dt>
<dd>(3.4-6.4)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Gemfibrozil 600Â mgÂ BID for 7Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">80Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.9<br>(1.6-2.2)</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>2.2</dd>
<dt>Â </dt>
<dd>(1.8-2.7)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Eltrombopag 75 mg QD, 5 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1.6</p>
<p>(1.4-1.7)</p>
</td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>2</dd>
<dt>Â </dt>
<dd>(1.8-2.3)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Darunavir 600 mg/ritonavir 100 mg BID, 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg QD for 7 days<br></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1.5</p>
<p>(1.0-2.1)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">2.4</p>
<p>(1.6-3.6)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Tipranavir/ritonavir combination 500Â mg/200mgÂ BID for 11Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1.4</p>
<p>(1.2-1.6)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">2.2</p>
<p>(1.8-2.7)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Dronedarone 400 mg BID</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Itraconazole 200 mg QD, 5 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg or 80Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1.4</p>
<p>(1.2-1.6)</p>
<p>1.3</p>
<p>(1.1-1.4)</p>
</td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>1.4</dd>
<dt>Â </dt>
<dd>(1.2-1.5)</dd>
<dt>Â </dt>
<dd>1.2</dd>
<dt>Â </dt>
<dd>(0.9-1.4)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ezetimibe 10 mg QD, 14 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10 mg QD for 14 days</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>1.2</dd>
<dt>Â </dt>
<dd>(0.9-1.6)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1.2</p>
<p>(0.8-1.6)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fosamprenavir/ritonavir 700Â mg/100Â mgÂ BID for 7Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1.1</p></td>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd>1.5</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fenofibrate 67Â mgÂ TID for 7Â days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">1.2</p>
<p>(1.1-1.3)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Rifampicin 450 mg QD, 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Aluminum &amp; magnesium hydroxide combination antacid</p>
<p>Administered simultaneously<br>Administered 2Â hours apart</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40Â mg<br>40Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.5</p>
<p>(0.4-0.5)</p>
<p>0.8</p>
<p>(0.7-0.9)</p>
</td>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>0.5</dd>
<dt>Â </dt>
<dd>(0.4-0.6)</dd>
<dt>Â </dt>
<dd>0.8</dd>
<dt>Â </dt>
<dd>(0.7-1.0)</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ketoconazole 200Â mgÂ BID for 7Â days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.0</p>
<p>(0.8-1.2)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.0</p>
<p>(0.7-1.3)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fluconazole 200Â mg QD for 11Â days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.1</p>
<p>(1.0-1.3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.1</p>
<p>(0.9-1.4)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Erythromycin 500Â mgÂ QID for 7Â days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.8</p>
<p>(0.7-0.9)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.7</p>
<p>(0.5-0.9)</p>
</td>
</tr>
</tbody>
</table>
<a name="_RefID0EDFAI"></a><table width="100%">
<caption><span>Table 5. Effect of Rosuvastatin Coadministration on Systemic Exposure To Other Drugs</span></caption>
<col width="23%">
<col width="51%">
<col width="13%">
<col width="13%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Rosuvastatin Dosage Regimen</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">Coadministered Drug</span></th>
</tr>
<tr>
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Mean Ratio (ratio with/without coadministered drug) No Effect = 1.0</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Name and Dose</span></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Change in AUC</span></th>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Change in C<span class="Sub">max</span></span></th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Clinically significant pharmacodynamic effects [see<span class="Italics"><a href="#williamsonbk1194553111202">Warnings and Precautions (5.3)</a></span>]</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40Â mg QD for 10 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Warfarin<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p>
<p>25Â mg single dose </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">R- Warfarin 1.0</p>
<p>(1.0-1.1)</p>
<p>S-Warfarin 1.1</p>
<p>(1.0-1.1)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">R-Warfarin 1.0</p>
<p>(0.9-1.0)</p>
<p>S-Warfarin 1.0</p>
<p>(0.9-1.1)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40Â mg QD for 12 days</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Digoxin </p>
<p>0.5Â mg single dose</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.0</p>
<p>(0.9-1.2)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.0</p>
<p>(0.9-1.2)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40Â mg QD for 28 days</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">Oral Contraceptive</p>
<p>(ethinyl estradiol 0.035Â mg &amp; norgestrel 0.180, 0.215 and 0.250Â mg) QD for 21 Days</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">EE 1.3</p>
<p>(1.2-1.3)</p>
<p>NG 1.3</p>
<p>(1.3-1.4)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">EE 1.3</p>
<p>(1.2-1.3)</p>
<p>NG 1.2</p>
<p>(1.1-1.3)</p>
</td>
</tr>
<tr class="Last"><td class="Botrule" colspan="4"><p class="First">EE = ethinyl estradiol, NG = norgestrel</p></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_aad51690-4728-43f1-8587-955e66c575e8"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_057d736a-59a1-48ce-a43c-25a5580505ba"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80Â mg/kg/day by oral gavage, the incidence of uterine stromal <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> was significantly increased in females at 80 mg/kg/day at systemic exposure 20Â times the human exposure at 40Â mg/day based on AUC. Increased incidence of <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> was not seen at lower doses. </p>
<p>In a 107-week carcinogenicity study in mice given 10, 60, 200 mg/kg/day by oral gavage, an increased incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span>/carcinoma was observed at 200 mg/kg/day at systemic exposures 20Â times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses. </p>
<p>Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span>, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the <span class="Italics">in vivo</span> mouse micronucleus test. </p>
<p>In rat fertility studies with oral gavage doses of 5, 15, 50Â mg/kg/day, males were treated for 9Â weeks prior to and throughout mating and females were treated 2Â weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50Â mg/kg/day (systemic exposures up to 10Â times the human exposure at 40Â mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30Â mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6â€‘month treatment at 30Â mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20Â times and in the monkey 10Â times the human exposure at 40Â mg/day based on body surface area. Similar findings have been seen with other drugs in this class.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="williamsonbk1194552853517"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology  and/or Pharmacology </h2>
<p class="First"><span class="Bold">Embryo-fetal Development</span></p>
<p>Rosuvastatin crosses the placenta and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25Â mg/kg oral gavage dose on gestation day 16 in rats.  A higher fetal tissue distribution (25% maternal plasma concentration) was observed in rabbits after a single oral gavage dose of 1Â mg/kg on gestation dayÂ 18.  </p>
<p>In female rats given oral gavage doses of 5, 15, 50Â mg/kg/day rosuvastatin before mating and continuing through dayÂ 7 postcoitus results in decreased fetal body weight (female pups) and delayed ossification at the high dose (systemic exposures 10 times the human exposure at 40Â mg/day based on AUC). </p>
<p>In pregnant rats given oral gavage doses of 2, 10, 50Â mg/kg/day from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred in groups given 50Â mg/kg/day, systemic exposures â‰¥Â 12 times the human exposure at 40Â mg/day based on body surface area.</p>
<p>In pregnant rabbits given oral gavage doses of 0.3, 1, 3Â mg/kg/day from gestation day 6 to lactation day 18 (weaning), exposures equivalent to the human exposure at 40Â mg/day based on body surface area, decreased fetal viability and maternal mortality was observed. </p>
<p>Rosuvastatin was not teratogenic in rats at â‰¤Â 25 mg/kg/day or in rabbits â‰¤Â 3 mg/kg/day (systemic exposures equivalent to the human exposure at 40Â mg/day based on AUC or body surface area, respectively).  </p>
<p><span class="Bold">Central Nervous System Toxicity</span></p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with several other members of this drug class. A chemically similar drug in this class produced dose-dependent optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in dogs, at a dose that produced plasma drug levels about 30Â times higher than the mean drug level in humans taking the highest recommended dose. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and partial <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in the interstitium of the choroid plexus was observed in a female dog sacrificed moribund at day 24Â at 90Â mg/kg/day by oral gavage (systemic exposures 100Â times the human exposure at 40Â mg/day based on AUC). <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">Corneal opacity</span> was seen in dogs treated for 52Â weeks at 6Â mg/kg/day by oral gavage (systemic exposures 20Â times the human exposure at 40Â mg/day based on AUC). <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span> were seen in dogs treated for 12Â weeks by oral gavage at 30Â mg/kg/day (systemic exposures 60Â times the human exposure at 40Â mg/day based on AUC). Retinal <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> and retinal loss were seen in dogs treated for 4Â weeks by oral gavage at 90Â mg/kg/day (systemic exposures 100Â times the human exposure at 40Â mg/day based on AUC). Doses â‰¤30Â mg/kg/day (systemic exposures â‰¤60 times the human exposure at 40Â mg/day based on AUC) did not reveal retinal findings during treatment for up to one year.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_5280e2d1-6210-45b2-a18e-58144a13187e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2dc1f591-b912-4595-b889-69536f706295"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> </h2>
<p class="First">CRESTOR reduces Totalâ€‘C, LDLâ€‘C, ApoB, nonHDLâ€‘C, and TG, and increases HDLâ€‘C, in adult patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>.  </p>
<p><span class="Italics">Dose-Ranging Study:</span> In a multicenter, double-blind, placebo-controlled, dose-ranging study in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> CRESTOR given as a single daily dose for 6Â weeks significantly reduced Totalâ€‘C, LDLâ€‘C, nonHDLâ€‘C, and ApoB, across the dose range (Table 6).</p>
<dl>
<dt>Â </dt>
<dd>Table . Dose-Response in Patients With <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Adjusted Mean % Change From Baseline at Week 6)</dd>
</dl>
<table width="100%">
<col width="23%">
<col width="6%">
<col width="12%">
<col width="11%">
<col width="18%">
<col width="10%">
<col width="7%">
<col width="12%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Dose</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">N</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">Total</span>â€‘<span class="Bold">C</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">LDL</span>â€‘<span class="Bold">C</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">Non-HDL</span>â€‘<span class="Bold">C</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">ApoB</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">TG</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">HDL</span>â€‘<span class="Bold">C</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Toprule"><p class="First">13</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-5</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-7</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-7</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-3</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-3</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First">CRESTOR </p>
<p>5 mg</p>
</td>
<td class="Botrule Lrule"><p class="First">17</p></td>
<td class="Botrule Lrule"><p class="First">-33</p></td>
<td class="Botrule Lrule"><p class="First">-45</p></td>
<td class="Botrule Lrule"><p class="First">-44</p></td>
<td class="Botrule Lrule"><p class="First">-38</p></td>
<td class="Botrule Lrule"><p class="First">-35</p></td>
<td class="Botrule Lrule Rrule"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">CRESTOR 10 mg</p></td>
<td class="Botrule Lrule"><p class="First">17</p></td>
<td class="Botrule Lrule"><p class="First">-36</p></td>
<td class="Botrule Lrule"><p class="First">-52</p></td>
<td class="Botrule Lrule"><p class="First">-48</p></td>
<td class="Botrule Lrule"><p class="First">-42</p></td>
<td class="Botrule Lrule"><p class="First">-10</p></td>
<td class="Botrule Lrule Rrule"><p class="First">14</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">CRESTOR 20 mg</p></td>
<td class="Botrule Lrule"><p class="First">17</p></td>
<td class="Botrule Lrule"><p class="First">-40</p></td>
<td class="Botrule Lrule"><p class="First">-55</p></td>
<td class="Botrule Lrule"><p class="First">-51</p></td>
<td class="Botrule Lrule"><p class="First">-46</p></td>
<td class="Botrule Lrule"><p class="First">-23</p></td>
<td class="Botrule Lrule Rrule"><p class="First">8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">CRESTOR 40 mg</p></td>
<td class="Botrule Lrule"><p class="First">18</p></td>
<td class="Botrule Lrule"><p class="First">-46</p></td>
<td class="Botrule Lrule"><p class="First">-63</p></td>
<td class="Botrule Lrule"><p class="First">-60</p></td>
<td class="Botrule Lrule"><p class="First">-54</p></td>
<td class="Botrule Lrule"><p class="First">-28</p></td>
<td class="Botrule Lrule Rrule"><p class="First">10</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Active-Controlled Study:</span> CRESTOR was compared with the HMGâ€‘CoA reductase inhibitors atorvastatin, simvastatin, and pravastatin in a multicenter, open-label, dose-ranging study of 2240 patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. After randomization, patients were treated for 6 weeks with a single daily dose of either CRESTOR, atorvastatin, simvastatin, or pravastatin (Figure 1 and Table 7).</p>
<p>Figure .	Percent LDLâ€‘	C Change by Dose of CRESTOR, Atorvastatin, Simvastatin, and Pravastatin at Week 6 in Patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></p>
<div class="Figure">
<a name="id1927"></a><img alt="figure one" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2c1a3c18-fa77-401b-8784-8e18b0d862f1&amp;name=3a498c46-5ad2-416a-875e-18e48b586954-02.jpg">
</div>
<p>Box plots are a representation of the 25th, 50th, and 75th percentile values, with whiskers representing the 10th and 90th percentile values. Mean baseline LDLâ€‘C: 189 mg/dL</p>
<p>Table . Percent Change in LDLâ€‘C From Baseline to Week 6 (LS Mean<a name="footnote-reference-4" href="#footnote-4" class="Sup">1</a>) by Treatment Group (sample sizes ranging from 156â€“167 patients per group)</p>
<table width="100%">
<col width="30%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="18%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>CRESTOR 10Â mg reduced LDL-C significantly more than atorvastatin 10 mg; pravastatin 10Â mg, 20Â mg, and 40Â mg; simvastatin 10Â mg, 20Â mg, and 40Â mg. (p&lt; 0.002)</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€ </a></dt>
<dd>CRESTOR 20Â mg reduced LDL-C significantly more than atorvastatin 20Â mg and 40Â mg; pravastatin 20Â mg and 40Â mg; simvastatin 20Â mg, 40Â mg, and 80Â mg. (p&lt; 0.002)</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€¡</a></dt>
<dd>CRESTOR 40Â mg reduced LDLâ€‘C significantly more than atorvastatin 40Â mg; pravastatin 40Â mg; simvastatin 40Â mg, and 80Â mg. (p&lt; 0.002)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Treatment Daily Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">10Â mg</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">20Â mg</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">40Â mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">80Â mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">CRESTOR</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-46<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">-52<a name="footnote-reference-6" href="#footnote-6" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">-55<a name="footnote-reference-7" href="#footnote-7" class="Sup">â€¡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">---</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Atorvastatin</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-37</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-43</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-48</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-51</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Simvastatin</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-28</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-35</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-39</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-46</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Pravastatin  </p></td>
<td class="Botrule Lrule" align="center"><p class="First">-20</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-24</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-30</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">---</p></td>
</tr>
</tbody>
</table>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">1</a></dt>
<dd>Corresponding standard errors are approximately 1.00</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ea326892-c648-42a4-8c79-ccd43f45bc47"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></h2>
<p class="First"><span class="Italics">Active-Controlled Study</span>: In a study of patients with heterozygous FH (baseline mean LDL of 291), patients were randomized to CRESTOR 20Â mg or atorvastatin 20Â mg. The dose was increased by 6-week intervals. Significant LDL-C reductions from baseline were seen at each dose in both treatment groups (Table 8).</p>
<p>Table .  Mean LDL-C Percentage Change from Baseline</p>
<table width="100%">
<col width="17%">
<col width="13%">
<col width="34%">
<col width="36%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">CRESTOR (n=435)</span><br><span class="Bold">LS Mean</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><span class="Bold"> (95% CI)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Atorvastatin (n=187)</span><br><span class="Bold"> LS Mean</span><a href="#footnote-8" class="Sup">*</a><span class="Bold"> (95% CI)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>LS Means are least square means adjusted for baseline LDL-C</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Week 6</p></td>
<td class="Botrule Lrule Toprule"><p class="First">20Â mg</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-47% (-49%, -46%)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">-38% (-40%, -36%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Week 12</p></td>
<td class="Botrule Lrule"><p class="First">40Â mg</p></td>
<td class="Botrule Lrule"><p class="First">-55% (-57%, -54%)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">-47% (-49%, -45%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Week 18</p></td>
<td class="Botrule Lrule"><p class="First">80Â mg</p></td>
<td class="Botrule Lrule"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule"><p class="First">-52% (-54%, -50%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d7aea8f4-063e-4ac8-b93e-a959473f1d58"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </h2>
<p class="First"><span class="Italics">Dose-Response Study:</span> In a double-blind, placebo-controlled dose-response study in patients with baseline TG levels from 273 to 817Â mg/dL, CRESTOR given as a single daily dose (5 to 40Â mg) over 6Â weeks significantly reduced serum TG levels (Table 9).</p>
<dl>
<dt>Â </dt>
<dd>Table . Dose-Response in  Patients With Primary <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> Over 6 Weeks Dosing        Median (Min, Max) Percent Change From Baseline</dd>
</dl>
<table width="100%">
<col width="17%">
<col width="15%">
<col width="16%">
<col width="17%">
<col width="17%">
<col width="16%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Dose</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">(n=26)</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">CRESTOR </span><br><span class="Bold">5Â mg</span><br><span class="Bold">(n=25)</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">CRESTOR </span><br><span class="Bold">10Â mg </span><br><span class="Bold">(n=23)</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">CRESTOR </span><br><span class="Bold">20Â mg </span><br><span class="Bold">(n=27)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">CRESTOR </span><br><span class="Bold">40Â mg </span><br><span class="Bold">(n=25)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Triglycerides</p></td>
<td class="Botrule Lrule Toprule"><p class="First">1 (-40, 72)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-21 (-58, 38)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-37 (-65, 5)</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-37 (-72, 11)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">-43 (-80, -7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">nonHDL-C</p></td>
<td class="Botrule Lrule"><p class="First">2 (-13, 19)</p></td>
<td class="Botrule Lrule"><p class="First">-29 (-43, -8)</p></td>
<td class="Botrule Lrule"><p class="First">-49 (-59, -20)</p></td>
<td class="Botrule Lrule"><p class="First">-43 (-74, 12)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">-51 (-62, -6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">VLDL-C</p></td>
<td class="Botrule Lrule"><p class="First">2 (-36, 53)</p></td>
<td class="Botrule Lrule"><p class="First">-25 (-62, 49)</p></td>
<td class="Botrule Lrule"><p class="First">-48 (-72, 14)</p></td>
<td class="Botrule Lrule"><p class="First">-49 (-83, 20)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">-56 (-83, 10)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Total-C</p></td>
<td class="Botrule Lrule"><p class="First">1 (-13, 17)</p></td>
<td class="Botrule Lrule"><p class="First">-24 (-40, -4)</p></td>
<td class="Botrule Lrule"><p class="First">-40 (-51, -14)</p></td>
<td class="Botrule Lrule"><p class="First">-34 (-61, -11)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">-40 (-51, -4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">LDL-C</p></td>
<td class="Botrule Lrule"><p class="First">5 (-30, 52)</p></td>
<td class="Botrule Lrule"><p class="First">-28 (-71, 2)</p></td>
<td class="Botrule Lrule"><p class="First">-45 (-59, 7)</p></td>
<td class="Botrule Lrule"><p class="First">-31 (-66, 34)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">-43 (-61, -3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">HDL-C</p></td>
<td class="Botrule Lrule"><p class="First">-3 (-25, 18)</p></td>
<td class="Botrule Lrule"><p class="First">Â 3Â (-38, 33)</p></td>
<td class="Botrule Lrule"><p class="First">8 (-8, 24)</p></td>
<td class="Botrule Lrule"><p class="First">22 (-5, 50)</p></td>
<td class="Botrule Lrule Rrule"><p class="First">17 (-14, 63)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3e0d63d4-03ca-4eab-8320-3a574e834ff2"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Primary Dysbetalipoproteinemia (Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipoproteinemia</span>)</h2>
<p class="First">In a randomized, multicenter, double-blind crossover study, 32 patients (27 with Ñ”2/Ñ”2 and 4 with apo E mutation [Arg145Cys] with primary dysbetalipoproteinemia (Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipoproteinemia</span>) entered a 6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to a sequence of treatments in conjunction with the TLC diet for 6Â weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10Â mg. CRESTOR reduced non HDLâ€‘C (primary end point) and circulating remnant lipoprotein levels. Results are shown in the table below.</p>
<a name="_RefID0EEGBI"></a><table width="100%">
<caption><span>Table 10. Lipid-modifying Effects of Rosuvastatin 10Â mg and 20Â mg in Primary Dysbetalipoproteinemia (Type III <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipoproteinemia</span>) after Six weeks by Median Percent Change (95% CI) from Baseline (N=32)</span></caption>
<col width="15%">
<col width="17%">
<col width="34%">
<col width="34%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Median at Baseline (mg/dL)</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Median percent change from baseline (95% CI) CRESTOR 10Â mg</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Median percent change from baseline (95% CI)  CRESTOR 20Â mg</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Total-C</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">342.5</p></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First">â€“ 43.3</p>
<p>(-46.9, â€“ 37.5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">-47.6</p>
<p>(-51.6,-42.8)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Triglycerides</p></td>
<td class="Botrule Lrule" align="center"><p class="First">503.5</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-40.1</p>
<p>(-44.9, -33.6)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-43.0</p>
<p>(-52.5, -33.1)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">NonHDL-C</p></td>
<td class="Botrule Lrule" align="center"><p class="First">294.5</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-48.2</p>
<p>(-56.7,  -45.6)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-56.4</p>
<p>(-61.4, -48.5)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">VLDL-C + IDL-C</p></td>
<td class="Botrule Lrule" align="center"><p class="First">209.5</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-46.8</p>
<p>(-53.7, -39.4)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-56.2</p>
<p>(-67.7, -43.7)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">LDL-C</p></td>
<td class="Botrule Lrule" align="center"><p class="First">112.5</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-54.4</p>
<p>(-59.1, -47.3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-57.3</p>
<p>(-59.4, -52.1)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">HDL-C</p></td>
<td class="Botrule Lrule" align="center"><p class="First">35.5</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">10.2</p>
<p>(1.9, 12.3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">11.2</p>
<p>(8.3, 20.5)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">RLP-C</p></td>
<td class="Botrule Lrule" align="center"><p class="First">82.0</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-56.4</p>
<p>(-67.1, -49.0)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-64.9</p>
<p>(-74.0, -56.6)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Apo-E</p></td>
<td class="Botrule Lrule" align="center"><p class="First">16.0</p></td>
<td class="Botrule Lrule" align="center">
<p class="First">-42.9</p>
<p>(-46.3, -33.3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">-42.5</p>
<p>(-47.1, -35.6)</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_baea7090-0850-4553-b00f-b8d122f72e37"></a><a name="section-13.5"></a><p></p>
<h2>14.5 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First"><span class="Italics">Dose-Titration Study:</span> In an open-label, forced-titration study, homozygous FH patients (n=40, 8â€‘63 years) were evaluated for their response to CRESTOR 20Â toÂ 40Â mg titrated at a 6â€‘week interval. In the overall population, the mean LDLâ€‘C reduction from baseline was 22%. About one-third of the patients benefited from increasing their dose from 20Â mg to 40Â mg with further LDL lowering of greater than 6%. In the 27 patients with at least a 15% reduction in LDLâ€‘C, the mean LDL-C reduction was 30% (median 28% reduction). Among 13 patients with an LDLâ€‘C reduction of &lt;15%, 3 had no change or an increase in LDLâ€‘C. Reductions in LDLâ€‘C of 15% or greater were observed in 3Â ofÂ 5 patients with known receptor negative status.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf58b45e-aef6-4b12-81d0-061ab2a24175"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Pediatric Patients with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span></h2>
<p class="First">In a double blind, randomized, multicenter, placebo-controlled, 12 week study, 176 (97 male and 79 female) children and adolescents with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> were randomized to rosuvastatin 5, 10 or 20 mg or placebo daily. Patients ranged in age from 10 to 17 years (median age of 14 years) with approximately 30% of the patients 10 to 13 years and approximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at least 1 year postmenarche. Mean LDL C at baseline was 233 mg/dL (range of 129 to 399). The 12 week double blind phase was followed by a 40 week open label dose-titration phase, where all patients (n=173) received 5 mg, 10 mg or 20 mg rosuvastatin daily.</p>
<p>Rosuvastatin significantly reduced LDL-C (primary end point), total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and ApoB levels at each dose compared to placebo.  Results are shown in Table 11 below.</p>
<a name="_RefID0E6NBI"></a><table width="100%">
<caption><span>Table 11. Lipid-modifying effects of rosuvastatin in pediatric patients 10 to 17 years of age with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (least-squares mean percent change from baseline to week 12)</span></caption>
<col width="19%">
<col width="8%">
<col width="15%">
<col width="16%">
<col width="16%">
<col width="13%">
<col width="13%">
<thead><tr class="First Last">
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Dose (mg)</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">N</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">LDL-C</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">HDL-C</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top"><span class="Bold">Total-C</span></th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">TG</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">ApoB</span></th>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Median percent change</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">â€ </a></dt>
<dd>Difference from placebo not statistically significant</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Toprule"><p class="First">46</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-1%</p></td>
<td class="Botrule Lrule Toprule"><p class="First">+7%</p></td>
<td class="Botrule Lrule Toprule"><p class="First">0%</p></td>
<td class="Botrule Lrule Toprule"><p class="First">-7%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">-2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">5</p></td>
<td class="Botrule Lrule"><p class="First">42</p></td>
<td class="Botrule Lrule"><p class="First">-38%</p></td>
<td class="Botrule Lrule"><p class="First">+4%<a name="footnote-reference-10" href="#footnote-10" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule"><p class="First">-30%</p></td>
<td class="Botrule Lrule"><p class="First">-13%<a href="#footnote-10" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule"><p class="First">-32%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">10</p></td>
<td class="Botrule Lrule"><p class="First">44</p></td>
<td class="Botrule Lrule"><p class="First">-45%</p></td>
<td class="Botrule Lrule"><p class="First">+11% <a href="#footnote-10" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule"><p class="First">-34%</p></td>
<td class="Botrule Lrule"><p class="First">-15%<a href="#footnote-10" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule"><p class="First">-38%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">20</p></td>
<td class="Botrule Lrule"><p class="First">44</p></td>
<td class="Botrule Lrule"><p class="First">-50%</p></td>
<td class="Botrule Lrule"><p class="First">+9%<a href="#footnote-10" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule"><p class="First">-39%</p></td>
<td class="Botrule Lrule"><p class="First">16%<a href="#footnote-10" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule"><p class="First">-41%</p></td>
</tr>
</tbody>
</table>
<p>At the end of the 12 week, double blind treatment period, the percentage of patients achieving the LDL C goal of less than 110 mg/dL (2.8 mmol/L) was 0% for placebo, 12% for rosuvastatin 5 mg, 41% for rosuvastatin 10 mg and 41% for rosuvastatin 20 mg. For the 40 week, open label phase, 71% of the patients were titrated to the maximum dose of 20 mg and 41% of the patients achieved the LDL C goal of 110 mg/dL. </p>
<p>The long-term efficacy of rosuvastatin therapy initiated in childhood to reduce morbidity and mortality in adulthood has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="williamsonbk1194897890156"></a><a name="section-13.7"></a><p></p>
<h2>14.7 Slowing of the Progression of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span></h2>
<p class="First">In the <span class="Italics">Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)</span> study, the effect of therapy with CRESTOR on carotid <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> was assessed by B-mode ultrasonography in patients with elevated LDLâ€‘C, at low risk (Framingham risk &lt;10% over ten years) for symptomatic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> and with subclinical <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> as evidenced by carotid intimal-medial thickness (cIMT).   In this double-blind, placebo-controlled clinical study 984 patients were randomized (of whom 876 were analyzed) in a 5:2 ratio to CRESTOR 40 mg or placebo once daily.  Ultrasonograms of the carotid walls were used to determine the annualized rate of change per patient from baseline to two years in mean maximum cIMT of 12 measured segments. The estimated difference in the rate of change in the maximum cIMT analyzed over all 12 carotid artery sites between patients treated with CRESTOR and placebo-treated patients was -0.0145 mm/year (95% CI â€“0.0196, â€“0.0093; p&lt; 0.0001).  </p>
<p>The annualized rate of change from baseline for the placebo group was +0.0131 mm/year (p&lt; 0.0001). The annualized rate of change from baseline for the group treated with CRESTOR was -0.0014 mm/year (p=0.32).</p>
<p>At an individual patient level in the group treated with CRESTOR, 52.1% of patients demonstrated an absence of disease progression (defined as a negative annualized rate of change), compared to 37.7% of patients in the placebo group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f858b2a7-3707-40d9-9002-bf31f98aaf0c"></a><a name="section-13.8"></a><p></p>
<h2>14.8 Primary Prevention of Cardiovascular Disease</h2>
<p class="First">In the <span class="Bold">J</span>ustification for the <span class="Bold">U</span>se of Statins in <span class="Bold">P</span>rimary Prevention: An <span class="Bold">I</span>ntervention <span class="Bold">T</span>rial <span class="Bold">E</span>valuating <span class="Bold">R</span>osuvastatin (JUPITER) study, the effect of CRESTOR (rosuvastatin calcium) on the occurrence of major cardiovascular (CV) disease events was assessed in 17,802 men (â‰¥50Â years) and women (â‰¥60 years) who had no clinically evident cardiovascular disease, LDLâ€‘C levels &lt;130Â mg/dL (3.3 mmol/l) and hsâ€‘CRP levels â‰¥2Â mg/L. The study population had an estimated baseline coronary heart disease risk of 11.6% over 10 years based on the Framingham risk criteria and included a high percentage of patients with additional risk factors such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (58%), low HDLâ€‘C levels (23%), cigarette smoking (16%), or a family history of premature CHD (12%). Study participants had a median baseline LDLâ€‘C of 108 mg/dL and hsCRP of 4.3Â mg/L. Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20Â mg once daily (n=8901) and were followed for a mean duration of 2 years. The JUPITER study was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in rosuvastatin-treated subjects. </p>
<p>The primary end point was a composite end point consisting of the time-to-first occurrence of any of the following major CV events: CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, hospitalization for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or an arterial revascularization procedure. </p>
<p>Rosuvastatin significantly reduced the risk of major CV events (252 events in the placebo group vs. 142 events in the rosuvastatin group) with a statistically significant (p&lt; 0.001) relative risk reduction of 44% and absolute risk reduction of 1.2% (see Figure 2). The risk reduction for the primary end point was consistent across the following predefined subgroups: age, sex, race, smoking status, family history of premature CHD, body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index, LDLâ€‘C, HDLâ€‘C, and hsCRP levels.</p>
<p>Figure . Time to first occurrence of major cardiovascular events in JUPITER</p>
<div class="Figure">
<a name="id2455"></a><img alt="figure two" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2c1a3c18-fa77-401b-8784-8e18b0d862f1&amp;name=3a498c46-5ad2-416a-875e-18e48b586954-03.jpg">
</div>
<p>The individual components of the primary end point are presented in Figure 3. Rosuvastatin significantly reduced the risk of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and arterial revascularization procedures. There were no significant treatment differences between the rosuvastatin and placebo groups for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to cardiovascular causes or hospitalizations for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>.</p>
<p>Rosuvastatin significantly reduced the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. 9 fatal events and 22 nonfatal events in rosuvastatin-treated subjects) and the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. 3 fatal events and 30 nonfatal events in rosuvastatin-treated subjects). </p>
<p>In a post-hoc subgroup analysis of JUPITER subjects (n=1405; rosuvastatin=725, placebo=680) with a hsCRP â‰¥2 mg/L and no other traditional risk factors (smoking, BPÂ â‰¥140/90 or taking antihypertensives, low HDLâ€‘C) other than age, after adjustment for high HDLâ€‘C, there was no significant treatment benefit with rosuvastatin treatment. </p>
<p>Figure . Major CV events by treatment group in JUPITER</p>
<div class="Figure">
<a name="id2461"></a><img alt="figure three" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2c1a3c18-fa77-401b-8784-8e18b0d862f1&amp;name=3a498c46-5ad2-416a-875e-18e48b586954-04.jpg">
</div>
<p>At one year, rosuvastatin increased HDLâ€‘C and reduced LDLâ€‘C, hsCRP, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and serum triglyceride levels (p&lt; 0.001 for all versus placebo).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_0b5cc245-4db3-4ca9-89a5-834271362021"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">CRESTOR<span class="Sup">Â®</span> (rosuvastatin calcium) Tablets are supplied as:</p>
<dl>
<dt>â€¢</dt>
<dd>NDC 0310-0755-90: 5Â mg. Yellow, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ5â€? on one side; bottle of 90 tablets</dd>
<dt>â€¢</dt>
<dd>NDC 0310-0751-90: 10Â mg. Pink, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ10â€? on one side; bottle of 90 tablets</dd>
<dt>â€¢</dt>
<dd>NDC 0310-0751-39: 10Â mg. Pink, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ10â€? on one side; unit dose packages of 100</dd>
<dt>â€¢</dt>
<dd>NDC 0310-0752-90: 20Â mg. Pink, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ20â€? on one side; bottles of 90</dd>
<dt>â€¢</dt>
<dd>NDC 0310-0752-39: 20Â mg. Pink, round, biconvex, coated tablets. Debossed â€œCRESTORâ€? and â€œ20â€?on one side; unit dose packages of 100</dd>
<dt>â€¢</dt>
<dd>NDC 0310-0754-30: 40Â mg. Pink, oval, biconvex, coated tablets. Debossed â€œCRESTORâ€? on one side and â€œ40â€? on the other side; bottles of 30</dd>
</dl>
<p><span class="Bold">Storage</span></p>
<p>Store at controlled room temperature, 20â€‘25ÂºC (68-77ÂºF) [see USP Controlled Room Temperature].  Protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="tylerr1190124974171"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be instructed not to take 2 doses of CRESTOR within 12 hours of each other.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1185a87a-ffd3-4a24-82a5-7fdf15435a77"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Skeletal Muscle Effects</h2>
<p class="First">Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if these muscle signs or symptoms persist after discontinuing CRESTOR. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5b792076-166f-459b-af38-9d6064e92eda"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Concomitant Use of Antacids</h2>
<p class="First">When taking CRESTOR with an aluminum and magnesium hydroxide combination antacid, the antacid should be taken at least 2 hours after CRESTOR administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16f3ca73-fab2-4d2e-b765-4b22397dc1c4"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Pregnancy</h2>
<p class="First">If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_90cea5b1-b720-402f-a8d2-ec21b2f8af36"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Liver Enzymes <br>It is recommended that liver enzyme tests be performed before the initiation of CRESTOR and if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur. All patients treated with CRESTOR should be advised to promptly report any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.<br>CRESTOR is a trademark of the AstraZeneca group of companies.<br>Â© AstraZeneca 2015<br>Licensed from SHIONOGI &amp; CO., LTD., Osaka, Japan   <br>Distributed by: <br>AstraZeneca Pharmaceuticals LP <br>Wilmington, DE 19850 <br>ASTRAZENECA <br>Rev.  June, 2015</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_9f0ccc3b-c68a-4fad-815f-45d8a01feece"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First">CRESTOR<span class="Sup">Â®</span>  (Kres-tor)</p>
<p>rosuvastatin calcium</p>
<p>Tablets </p>
<p>Read this Patient Information carefully before you start taking CRESTOR and each time you get a refill.  There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. </p>
<p>If you have any questions about CRESTOR, ask your doctor. Only your doctor can determine if CRESTOR is right for you. </p>
<p><span class="Bold">What is CRESTOR?</span></p>
<p>CRESTOR is a prescription medicine that contains a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medicine called rosuvastatin calcium.  CRESTOR is used along with diet to:</p>
<dl>
<dt>â€¢</dt>
<dd>lower the level of your â€œbadâ€? <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL)</dd>
<dt>â€¢</dt>
<dd>increase the level of your â€œgoodâ€? <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL)</dd>
<dt>â€¢</dt>
<dd>lower the level of fat in your blood (triglycerides)</dd>
<dt>â€¢</dt>
<dd>slow the buildup of fatty deposits (plaque) in the walls of blood vessels</dd>
</dl>
<p>CRESTOR is for patients who cannot control their <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels by diet and exercise alone.  CRESTOR is used  to reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> in men 50 years of age and older and women 60 years of age and older who do not have known heart disease but do have certain additional risk factors.</p>
<p>It is not known if CRESTOR is safe and effective in people who have Fredrickson Type I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.  It is not known if CRESTOR is safe and effective in children under 10 years of age or in girls who have not started their period (menses).</p>
<p><span class="Bold">Who should not take CRESTOR?</span></p>
<p><span class="Bold">Do not take CRESTOR if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to rosuvastatin calcium or any of the ingredients in CRESTOR.  See the end of this leaflet for a complete list of ingredients in CRESTOR.</dd>
<dt>â€¢</dt>
<dd>have liver problems.</dd>
<dt>â€¢</dt>
<dd>are pregnant or think you may be pregnant, or are planning to become pregnant. CRESTOR may harm your unborn baby. If you become pregnant, stop taking CRESTOR and call your doctor right away.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding. Medicines like CRESTOR can pass into your breast milk and may harm your baby.  It is not known if CRESTOR passes into your breast milk.  You and your doctor should decide the best way to feed your baby if you take CRESTOR.</dd>
</dl>
<p><span class="Bold">What should I tell my  doctor before and while taking CRESTOR?</span></p>
<p><span class="Bold">Tell your doctor if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
<dt>â€¢</dt>
<dd>have or have had kidney problems</dd>
<dt>â€¢</dt>
<dd>have or have had liver problems</dd>
<dt>â€¢</dt>
<dd>drink more than 2 glasses of alcohol daily</dd>
<dt>â€¢</dt>
<dd>have thyroid problems</dd>
<dt>â€¢</dt>
<dd>are 65 years of age or older</dd>
<dt>â€¢</dt>
<dd>are of Asian descent</dd>
<dt>â€¢</dt>
<dd>are pregnant or think you may be pregnant, or are planning to become pregnant</dd>
<dt>â€¢</dt>
<dd>are breastfeeding</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. </p>
<p>Talk to your doctor before you start taking any new medicines.</p>
<p>Taking CRESTOR with certain other medicines may affect each other causing side effects.  CRESTOR may affect the way other medicines work, and other medicines may affect how CRESTOR works. </p>
<p>Especially tell your doctor if you take:</p>
<dl>
<dt>â€¢</dt>
<dd>cyclosporine (a medicine for your immune system)</dd>
<dt>â€¢</dt>
<dd>gemfibrozil (a fibric acid medicine for lowering <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>)</dd>
<dt>â€¢</dt>
<dd>anti-viral medicines including HIV or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C protease inhibitors (such as lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, or simeprevir) </dd>
<dt>â€¢</dt>
<dd>certain anti-fungal medicines (such as itraconazole, ketoconazole and fluconazole</dd>
<dt>â€¢</dt>
<dd>coumarin anticoagulants (medicines that prevent blood clots, such as warfarin)</dd>
<dt>â€¢</dt>
<dd>niacin or nicotinic acid</dd>
<dt>â€¢</dt>
<dd>fibric acid derivatives (such as fenofibrate)</dd>
<dt>â€¢</dt>
<dd>colchicine (a medicine used to treat <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>)</dd>
</dl>
<p>Ask your doctor or pharmacist for a list of these medicines if you are not sure.</p>
<p>Know all of the medicines you take. Keep a list of them to show your doctor and pharmacist when you get new medicine. </p>
<p><span class="Bold">How should I take CRESTOR?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take CRESTOR exactly as your doctor tells you to take it. </dd>
<dt>â€¢</dt>
<dd>Take CRESTOR, by mouth, 1 time each day.  Swallow the tablet whole.</dd>
<dt>â€¢</dt>
<dd>CRESTOR can be taken at any time of day, with or without food.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not</span> change your dose or stop CRESTOR without talking to your doctor, even if you are feeling well. </dd>
<dt>â€¢</dt>
<dd>Your doctor may do blood tests to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels before and during your treatment with CRESTOR. Your doctor may change your dose of CRESTOR if needed.</dd>
<dt>â€¢</dt>
<dd>Your doctor may start you on a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering diet before giving you CRESTOR. Stay on this diet when you take CRESTOR. Wait at least 2 hours after taking CRESTOR to take an antacid that contains a combination of aluminum and magnesium hydroxide. </dd>
<dt>â€¢</dt>
<dd>If you miss a dose of CRESTOR, take it as soon as you remember. </dd>
<dt>â€¢</dt>
<dd>However, <span class="Bold">do not take 2Â doses of CRESTOR within 12Â hours of each other. </span>
</dd>
<dt>â€¢</dt>
<dd>If you take too much CRESTOR or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or go to the nearest hospital emergency room right away. </dd>
</dl>
<p><span class="Bold">What are the Possible Side Effects of CRESTOR?</span></p>
<p><span class="Bold">CRESTOR may cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> (<span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>).  </span>Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <span class="Bold">Tell your doctor right away if:</span><dl>
<dt>â€¢</dt>
<dd><span class="Bold">you have unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, especially if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or feel more tired than usual, while you take CRESTOR.</span></dd>
<dt>â€¢</dt>
<dd>you have muscle problems that do not go away even after your doctor has told you to stop taking CRESTOR.  Your doctor may do further tests to diagnose the cause of your muscle problems.</dd>
</dl>
</dd>
<dt>Â </dt>
<dd>Your chances of getting muscle problems are higher if you:<dl>
<dt>â€¢</dt>
<dd>are taking certain other medicines while you take CRESTOR</dd>
<dt>â€¢</dt>
<dd>are 65 years of age or older</dd>
<dt>â€¢</dt>
<dd>have thyroid problems (<span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>) that are not controlled</dd>
<dt>â€¢</dt>
<dd>have kidney problems</dd>
<dt>â€¢</dt>
<dd>are taking higher doses of CRESTOR</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Liver problems.</span> Your doctor should do blood tests to check your liver before you start taking CRESTOR and if you have symptoms of liver problems while you take CRESTOR. Call your doctor right away if you have any of the following symptoms of liver problems:<dl>
<dt>â€¢</dt>
<dd>feel unusually tired or weak</dd>
<dt>â€¢</dt>
<dd>loss of appetite</dd>
<dt>â€¢</dt>
<dd>upper belly <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>â€¢</dt>
<dd>dark urine</dd>
<dt>â€¢</dt>
<dd>yellowing of your skin or the whites of your eyes</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">The most common side effects may include: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </p>
<p>Additional side effects that have been reported with CRESTOR include</p>
<p><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of CRESTOR.  For more information, ask your doctor or pharmacist.  Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store CRESTOR?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store CRESTOR at room temperature, between 68Â°F to 77Â°F (20Â°C to 25Â°C) and in a dry place. </dd>
<dt>â€¢</dt>
<dd>Safely throw away medicine that is out of date or no longer needed.</dd>
</dl>
<p><span class="Bold">Keep CRESTOR and all medicines out of the reach of children. </span></p>
<p><span class="Bold">What are the Ingredients in CRESTOR? </span></p>
<p><span class="Bold">Active Ingredient:</span> rosuvastatin as rosuvastatin calcium </p>
<p><span class="Bold">Inactive Ingredients:</span> microcrystalline cellulose NF, lactose monohydrate NF, tribasic calcium phosphate NF, crospovidone NF, magnesium stearate NF, hypromellose NF, triacetin NF, titanium dioxide USP, yellow ferric oxide, and red ferric oxide NF. </p>
<p><span class="Bold">General Information about the safe and effective use of CRESTOR</span></p>
<p>Most of the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood is made in the liver. CRESTOR works by reducing <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in two ways: CRESTOR blocks an enzyme in the liver causing the liver to make less <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and CRESTOR increases the uptake and breakdown by the liver of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> already in the blood.</p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use CRESTOR for a condition for which it was not prescribed. Do not give CRESTOR to other people, even if they have the same medical condition you have. It may harm them. </p>
<p>This  Patient Information summarizes the most important information about CRESTOR. If you would like more information, talk to your doctor. You can ask your pharmacist or doctor for information about CRESTOR that is written for health professionals.</p>
<p>For more information, go to the CRESTOR website at www.crestor.com or call 1-800-CRESTOR. </p>
<p>CRESTOR is a trademark of the AstraZeneca group of companies. </p>
<p>Â© AstraZeneca 2015</p>
<p>Licensed from SHIONOGI &amp; CO., LTD., Osaka, Japan </p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP </p>
<p>Wilmington, DE 19850 </p>
<p>Revised June, 2015</p>
<p>ASTRAZENECA </p>
<p>Repackaged by Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>L37412460314A</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_27827639-edc6-4e68-a008-3624157decaf"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">Crestor 10 mg Tablets</p>
<p>Rosuvastatin calcium</p>
<p>10 Tablets</p>
<div class="Figure">
<a name="id1954281680"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2c1a3c18-fa77-401b-8784-8e18b0d862f1&amp;name=image-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CRESTORÂ 		
					</strong><br><span class="contentTableReg">rosuvastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-6921(NDC:0310-0751)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSUVASTATIN CALCIUM</strong> (ROSUVASTATIN) </td>
<td class="formItem">ROSUVASTATIN</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10;crestor</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-6921-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021366</td>
<td class="formItem">12/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>AstraZeneca PLC (230790719)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-6921)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b31de5ba-5ce2-4b9a-b141-867d9e107ca9</div>
<div>Set id: 2c1a3c18-fa77-401b-8784-8e18b0d862f1</div>
<div>Version: 4</div>
<div>Effective Time: 20150617</div>
</div>
</div>Â <div class="DistributorName">Cardinal Health</div></p>
</body></html>
